Research programme: interferon alpha-2b extended release - GeneMedix/SkyePharma
Latest Information Update: 02 May 2007
At a glance
- Originator GeneMedix; SkyePharma PLC
- Class Interferons
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer; Hepatitis B; Hepatitis C